Tag: Market withdrawal

Tesamorelin, marketed under brand names like Egrifta WR, is not banned and remains an FDA-approved treatment for HIV-associated lipodystrophy. The persistent question of "Why was tesamorelin banned?" stems from regulatory events and confusion surrounding different formulations and international market applications. This article clarifies the drug's true regulatory history.

In 1975, a cluster of patient deaths in Finland shocked the pharmaceutical industry and led to the dramatic withdrawal of the groundbreaking antipsychotic, clozapine, from the market. This initial safety scare is why was clozapine taken off the market, forever changing the drug's regulatory path and perception, despite its eventual reintroduction under stringent safety protocols.

Over 130 drugs were withdrawn from the market for safety reasons between 1990 and 2010 alone. Understanding what drugs have been discontinued is crucial for patient safety, as manufacturers and regulatory bodies frequently remove medications for various reasons, from newly discovered risks to business decisions.